Triptans (Serotonin, 5-HT1B/1D Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials

  title={Triptans (Serotonin, 5-HT1B/1D Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials},
  author={Mat{\'i}as Ferrari and P Goadsby and KI Roon and R. B. Lipton},
  pages={633 - 658}
The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs. [] Key Method We asked pharmaceutical companies and the principal investigators of company-independent trials for the ‘raw patient data’ of all double-blind, randomized, controlled, clinical trials with oral triptans in migraine. All data were cross-checked with published or presented data.

A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine

  • J. Pascual
  • Medicine
    Expert opinion on pharmacotherapy
  • 2004
Control head-to-head data and a meta-analysis of 53 randomised, placebo-controlled trials of oral triptans in > 24,000 patients have shown that rizatriptan 10 mg offers efficacy advantages over oral sumatripta 50 and 100 mg and other oral triPTans, both in terms of speed of onset of action and consistency.

Double-Blind Clinical Trials of Oral Triptans Vs Other Classes of Acute Migraine Medication — A Review

It is found that experience in clinical practice suggests that, for many patients, oral triptans are superior to non-specific acute treatments, creating a discrepancy between clinical trials results and clinical practice experience.

New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors

Results from studies with BI 44370 TA do not support broad concern about a class effect, and further studies are ongoing in this respect, suggesting that iNOS is very unlikely to be a promising target.

Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials

The use of ubrogepant as an acute treatment of episodic migraine in adults led to a greater percentage of freedom from pain and absence of the most bothersome symptoms at 2 h post-dose and was not related to an increased risk for adverse events.

Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs

None of these reviewed treatments are likely to fulfill patients' expectations, and the advancement of acute migraine drugs should likely depend on different mechanisms from current 5-HT-related drugs.

Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials

In this meta-analysis, the use of lasmiditan as an acute treatment for episodic migraine in adults led to a greater percentage of freedom of pain and the absence of the most bothersome symptoms at 2 h post-dose.



311C90, A new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine

Oral 311C90 (5 and 25 mg) is highly effective and well tolerated in the acute treatment of migraine and the response rates and treatment differences compared with placebo suggest possible superiority over existing antimigraine therapies.

Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study

The dose response data suggest that lower doses of oral zolmitriptan would also offer significant efficacy, and the most commonly reported adverse events were asthenia, dizziness, paraesthesia and feelings of heaviness.

311C90: Long-term efficacy and tolerability profile for the acute treatment of migraine

The efficacy profile and the nature/incidence of adverse events reported appear to be consistent with previous 311C90 studies, and the dosing regimen was well tolerated during multiple exposures.

The Long‐term Tolerability and Efficacy of Oral Zolmitriptan (Zomig, 31X90) in the Acute Treatment of Migraine. An International Study

This international open‐label study evaluated the tolerability and efficacy of zolmitriptan (Zomig®, 311C90), a selective 5‐HT1B/1D receptor agonist in the long‐term treatment of multiple migraine

311C90 (Zolmitriptan), A Novel Centrally and Peripheral Acting Oral 5-Hydroxytryptamine-1D Agonist: A Comparison of Its Absorption During A Migraine Attack and in A Migraine-Free Period

The oral absorption of a 10-m. oral dose of the novel 5-hydroxytryptamine (5HT1D) agonist, 311C90, was compared during a moderate or severe migraine headache and in a migraine-free period in an open,

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.

The antimigraine effect of 10- and 20-mg rizatriptan was superior to placebo, and comparable with that of 100-mg sum atriptan succinate, although it was associated with a high frequency of adverse events.

Double-Blind, Placebo-Controlled, Dose-Finding Study of Rizatriptan (MK-462) in the Acute Treatment of Migraine

Patients who took rizatriptan 5 mg and 10 mg were significantly less functionally disabled than those who took placebo at 1.5 and 2n post-dose, and riz atriptan 10 mg was consistently more effective than 5 mg, although the differences were not statistically significant.

Efficacy and Adverse Events of Subcutaneous, Oral, and Intranasal Sumatriptan Used for Migraine Treatment: A Systematic Review Based on Number Needed To Treat

  • P. Tfelt-Hansen
  • Medicine
    Cephalalgia : an international journal of headache
  • 1998
Therapeutic gain analysis during the first 2 h showed that subcutaneous sumatriptan was the fastest-acting form of administration, and this form in a dose of 6 mg is significantly more efficacious than 100 mg of oral sum atriptan, but causes more adverse events than oral sumAtriptan.